News Quantified

STOK – stoke therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.

Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $24.00 price target on the stock.

Stoke CEO exits; Medicare drug price talks advance [Yahoo! Finance]

Stoke Therapeutics Stock Slips as CEO Steps Down [Yahoo! Finance]

4.8%

BEAT

-4.3%

BEAT

-1.2%

BEAT

Chardan Capital

Chardan Capital

Needham & Company LLC

Form 4 Stoke Therapeutics, Inc. For: Mar 31 Filed by: LEVIN ARTHUR A

Form 4 Stoke Therapeutics, Inc. For: Mar 20 Filed by: SMITH IAN F

Form 4 Stoke Therapeutics, Inc. For: Mar 20 Filed by: TZIANABOS ARTHUR

Form 4 Stoke Therapeutics, Inc. For: Mar 20 Filed by: Leggett Thomas

Form 4 Stoke Therapeutics, Inc. For: Mar 19 Filed by: LEVIN ARTHUR A

Top News Gainers

10/25 Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 9.1%

3/23 Form 10-K Stoke Therapeutics, Inc. For: Dec 31 8.8%

2/14 Form SC 13G/A Stoke Therapeutics, Inc. Filed by: Cormorant Asset Management, LP 6.7%

10/2 Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: RTW INVESTMENTS, LP 6.6%

11/1 Form 4 Stoke Therapeutics, Inc. For: Oct 30 Filed by: WONG RODERICK 6.1%

9/30 Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference 5.9%

8/14 Form 8-K Stoke Therapeutics, Inc. For: Aug 14 4.4%

4/15 Form 8-K Stoke Therapeutics, Inc. For: Apr 14 4.2%

8/1 Stoke Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference 4.1%

11/25 Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting 4.1%

Top News Decliners

3/23 Stoke Therapeutics Reports Full Year 2019 Financial Results and Provides Business Updates -11.7%

2/24 Stoke Therapeutics to Present at 40th Annual Cowen Health Care Conference -9.5%

12/23 Stoke Therapeutics Added to NASDAQ Biotechnology Index -8.4%

11/12 Stoke Therapeutics (NASDAQ: STOK) is now covered by analysts at BTIG Research. They set a "buy" rating and a $46.00 price target on the stock. -8.0%

10/16 Stoke Therapeutics Strengthens Leadership Team With Appointments of Robin A. Walker, J.D., as Senior Vice President, Chief Legal Officer and Joan Wood as Head of Human Resources -7.3%

10/8 Why Shares of Stoke Therapeutics Plummeted in September [The Motley Fool] -7.1%

9/11 Stoke Therapeutics Added to Russell 2000 and 3000 Indexes -6.6%

6/21 Form 4 Stoke Therapeutics, Inc. For: Jun 21 Filed by: ATP III GP, Ltd. -6.5%

12/7 Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome -6.5%

9/18 Stoke Therapeutics (NASDAQ: STOK) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -6.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day